Stoke Therapeutics (STOK)
(Delayed Data from NSDQ)
$14.63 USD
+0.38 (2.67%)
Updated Aug 16, 2024 04:00 PM ET
After-Market: $14.64 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Income Statements
Fiscal Year end for Stoke Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 9 | 12 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 9 | 12 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 124 | 117 | 86 | 53 | 36 |
Income After Depreciation & Amortization | -115 | -104 | -86 | -53 | -36 |
Non-Operating Income | 10 | 3 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -105 | -101 | -86 | -52 | -32 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -105 | -101 | -86 | -52 | -32 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -105 | -101 | -86 | -52 | -32 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -113 | -103 | -85 | -52 | -35 |
Depreciation & Amortization (Cash Flow) | 2 | 1 | 1 | 1 | 0 |
Income After Depreciation & Amortization | -115 | -104 | -86 | -53 | -36 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 44.00 | 38.90 | 36.74 | 33.49 | 17.97 |
Diluted EPS Before Non-Recurring Items | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 |
Diluted Net EPS (GAAP) | -2.38 | -2.60 | -2.34 | -1.56 | -1.80 |
Fiscal Year end for Stoke Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 4.83 | 4.22 | 2.80 | 3.31 | -2.48 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 4.83 | 4.22 | 2.80 | 3.31 | -2.48 |
SG&A, R&D, and Dept/Amort Expenses | 34.18 | 32.59 | 32.39 | 30.54 | 30.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | -29.35 | -28.37 | -29.59 | -27.23 | -33.26 |
Non-Operating Income | 3.65 | 2.00 | 2.63 | 2.69 | 2.61 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -25.70 | -26.37 | -26.96 | -24.54 | -30.65 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -25.70 | -26.37 | -26.96 | -24.54 | -30.65 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -25.70 | -26.37 | -26.96 | -24.54 | -30.65 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 55.77 | 46.25 | 44.96 | 44.27 | 44.19 |
Diluted EPS Before Non-Recurring Items | -0.46 | -0.57 | -0.60 | -0.55 | -0.69 |
Diluted Net EPS (GAAP) | -0.46 | -0.57 | -0.61 | -0.55 | -0.69 |